Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Sees Significant Decline in Short Interest

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) saw a significant decrease in short interest in August. As of August 14th, there was short interest totaling 9,037 shares, a decrease of 80.3% from the July 30th total of 45,910 shares. Based on an average trading volume of 42,184 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the company’s shares are short sold.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Baird Financial Group Inc. increased its position in shares of Barinthus Biotherapeutics by 108.2% during the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after acquiring an additional 100,000 shares during the last quarter. Rangeley Capital LLC raised its position in shares of Barinthus Biotherapeutics by 88.8% in the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after purchasing an additional 75,024 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Barinthus Biotherapeutics by 115.8% during the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock valued at $100,000 after buying an additional 76,800 shares during the last quarter. 25.20% of the stock is owned by hedge funds and other institutional investors.

Barinthus Biotherapeutics Stock Down 1.1%

Shares of BRNS traded down $0.01 during mid-day trading on Friday, reaching $0.72. 6,406 shares of the stock traded hands, compared to its average volume of 52,548. The firm has a market cap of $29.54 million, a price-to-earnings ratio of -0.70 and a beta of -0.39. The stock has a fifty day simple moving average of $0.62 and a 200 day simple moving average of $0.63. Barinthus Biotherapeutics has a 12-month low of $0.51 and a 12-month high of $1.83.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.02. On average, equities research analysts expect that Barinthus Biotherapeutics will post -0.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BRNS has been the subject of a number of research reports. Zacks Research raised shares of Barinthus Biotherapeutics to a “hold” rating in a research report on Wednesday. Weiss Ratings raised Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.00.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.